| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_82ae8798cdec6cc8f8ad3eb62813831e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-351
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-533
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2330-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-111
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H99-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-549
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H1-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate |
2015-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32688133056c9c8fb5d43dceb323b600
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51d22e9d92add15dc5bac8f903f04aab |
| publicationDate |
2020-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2747842-T3 |
| titleOfInvention |
Ligand-modified double-stranded nucleic acids |
| abstract |
A double stranded nucleic acid (dsNA) comprising: an upstream strand comprising 21 to 83 nucleotides; an antisense strand comprising 15 to 39 nucleotides; a double formed by said sense and antisense strand, having a length of 15 to 35 base pairs; wherein the dsNA comprises a discontinuity between the 5 'terminus of the sense strand and the 3' terminus of the antisense strand or between the 3 'terminus of the sense strand and the 5' terminus of the antisense strand; wherein the sense strand comprises a tetraloop and the tetraloop comprises at least one ligand conjugated nucleotide, wherein the ligand is GalNAc; and wherein said antisense strand is complementary to a target mRNA together with at least 15 nucleotides of said antisense strand and said double-stranded nucleic acid reduces expression of the target gene when said double-stranded nucleic acid is introduced into a mammalian or mammalian cell, and preferably wherein the tetraloop comprises one, two, three, or four conjugated ligand nucleotides and each of the ligands is GalNAc. |
| priorityDate |
2014-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |